Recombinant Human Flt3 Protein，His

Flt3 (Fms-like tyrosine kinase 3) is a receptor tyrosine kinase primarily expressed in hematopoietic stem and progenitor cells, playing a crucial role in their proliferation, survival, and differentiation. Aberrant Flt3 signaling is implicated in various hematological malignancies, particularly acute myeloid leukemia (AML), where mutations leading to its constitutive activation are often found. Given its significance in leukemia pathogenesis, Flt3 has emerged as a promising therapeutic target, and the development of Flt3 inhibitors is an area of active research. Understanding the structural and functional properties of Flt3 through studies involving recombinant proteins is essential for designing targeted therapies. Recombinant Flt3 proteins can be used to investigate its activation mechanisms, assess binding affinities of various ligands, and identify potential inhibitors. Furthermore, these studies provide insights into the downstream signaling pathways activated by Flt3, contributing to a better understanding of hematopoiesis and leukemia. The exploration of Flt3's role in normal and malignant hematopoiesis is critical for developing novel therapies that can improve clinical outcomes for patients with Flt3-mutated leukemias. Overall, the research surrounding Flt3 recombinant proteins not only aids in elucidating the biological functions of this receptor but also holds potential for the advancement of targeted treatments in hematological cancers.